| Not Yet Recruiting | Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroe Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2026-02-26 |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Per Ovarian Cancers | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCA Metastatic Colorectal Cancer (CRC) | Phase 2 | 2026-02-01 |
| Recruiting | Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expres Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent | Phase 2 | 2026-01-01 |
| Not Yet Recruiting | Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma | — | 2025-12-25 |
| Not Yet Recruiting | Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadju NSCLC, NSCLC (Non-small Cell Lung Cancer) | Phase 2 | 2025-12-18 |
| Recruiting | Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | Phase 2 | 2025-12-01 |
| Recruiting | A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable N NSCLC | Phase 2 | 2025-09-04 |
| Not Yet Recruiting | A Study on Immunotherapy Combined With Radiotherapy for Esophagogastric Junction/Gastric Adenocarcinoma Esophagogastric Junction/Gastric Adenocarcinoma | Phase 2 | 2025-07-01 |
| Not Yet Recruiting | Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer Mouth Neoplasms, Neoadjuvant Therapy, Immunotherapy | Phase 2 | 2025-06-15 |
| Not Yet Recruiting | Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab i Squamous Cell Lung Cancer | Phase 2 | 2025-06-01 |
| Recruiting | Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma | Phase 2 | 2025-05-16 |
| Active Not Recruiting | Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2024-12-02 |
| Recruiting | MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC Non-small Cell Lung Cancer | — | 2024-02-01 |
| Unknown | High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM Colorectal Liver Metastases | Phase 1 | 2023-09-20 |
| Active Not Recruiting | Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2023-06-10 |
| Completed | Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal Carcin Nasopharyngeal Carcinoma, Radiation-Induced Temporal Lobe Injury | — | 2023-06-01 |
| Unknown | Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamou Non-squamous NSCLC | Phase 2 | 2023-03-15 |
| Unknown | Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia COVID-19 Pneumonia | Phase 2 | 2023-01-01 |
| Completed | Precision Nursing vs Conventional Care in Laparoscopic Colorectal Cancer Surgery: A Randomized Controlled Tria Colorectal Cancer | N/A | 2023-01-01 |
| Active Not Recruiting | Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC) Lung Cancer, Non-small Cell | Phase 2 | 2022-10-27 |
| Unknown | RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2 Biliary Tract Cancer | Phase 2 | 2022-08-01 |
| Unknown | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation | Phase 1 / Phase 2 | 2022-05-01 |
| Unknown | Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carc Locally Advanced Esophageal Carcinoma | Phase 2 | 2022-04-29 |
| Unknown | A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM. GBM | N/A | 2022-03-01 |
| Active Not Recruiting | Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Ran Esophageal Cancer | Phase 3 | 2021-06-01 |
| Unknown | Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cance Advanced Colorectal Cancer | Phase 1 / Phase 2 | 2021-06-01 |
| Unknown | A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedot Diffuse Large B-Cell Lymphoma (DLBCL) | — | 2019-12-12 |
| Unknown | A Study of Cetuximab Plus Raltitrexed for Maintenance Treatment in Advanced Colorectal Cancer Colorectal Cancer | Phase 2 | 2019-11-28 |
| Unknown | A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer Advanced Colorectal Cancer | Phase 2 | 2019-09-01 |
| Unknown | Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Nasopharyngeal Carcinoma | Phase 2 | 2019-06-01 |
| Completed | An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer Non Small Cell Lung Cancer | — | 2017-12-01 |
| Unknown | Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma Hepatocellular Carcinoma | N/A | 2017-03-15 |
| Unknown | Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer Advanced Colorectal Cancer | Phase 2 | 2017-02-15 |
| Unknown | Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Canc Head and Neck Squamous Cell Cancer | Phase 3 | 2015-06-01 |
| Terminated | NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation Nasopharyngeal Carcinoma | Phase 2 | 2012-09-01 |
| Completed | Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) Nasopharyngeal Carcinoma | Phase 1 / Phase 2 | 2010-05-01 |